Roche

The SMI closed 0.4% higher at 14,811 points, supported by defensive heavyweights such as Roche, Nestlé and Novartis, which gained up to 2.3%. Europe’s stock markets were under pressure from steep losses in technology stocks, notably Intel and Amazon. Among individual stocks, Julius Bär plans a share buyback program of up to CHF 600 million starting on Nov. 2, and Sandoz gave back part of the previous day’s gains after slightly narrowing its sales forecast. » Plus sur finanzen.net

Roche is launching the automated tissue test Ventana BAP1 (SP527) worldwide, intended to help distinguish malignant mesotheliomas from other tumors and benign changes. The test is registered in the US as an in vitro diagnostic class I device and approved in the EU under the IVDR as a class C product. Together with two recently introduced tests, the procedure is meant to reduce tissue consumption and thereby preserve more material for molecular analyses; no information on price or revenue potential was provided. » Plus sur finanzen.net

Roche has received CE marking for the Cobas smart e. The compact immunoassay analyzer for smaller laboratories and clinics offers a planned test menu of over 100 assays across areas such as cardiovascular, metabolic, oncology and infections on roughly 0.9 m², uses Elecsys technology and the same reagents as larger cobas systems, delivers reaction times of at most 18 minutes for over 90% of the assays, and is intended to improve local diagnostics and result comparability between sites. » Plus sur finanzen.net